p53, p63 and p73 expression in squamous cell carcinomas of the head and neck and their response to cisplatin exposure

Advances in Oto-Rhino-Laryngology

Volumn 62, Issue , 2005, Pages 58-71

  Balz, Vera ^a   Scheckenbach, Kathrin ^a   Gwosdz, Christian ^a   Bier, Henning ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33644614461     PISSN: 00653071     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (44)

1. Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature 2000;408:307-310.
2. Balz V, Scheckenbach K, Götte K, Bockmühl U, Petersen I, Bier H: Is the inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res 2003;63:1188-1191.
3. Weinberg WC, Azzoli CG, Chapman K, Levine AJ, Yuspa SH: p53-mediated transcriptional activity increases in differentiating epidermal keratinocytes in association with decreased p53 protein. Oncogene 1995;10:2271-2279.
4. Schmale H, Bamberger C: A novel protein with strong homology to the tumor suppressor p53. Oncogene 1997;15:1363-1367.
5. Osada M, Ohba M, Kawahara C, Ishioka C, Kanamaru R, Katoh I, Ikawa Y, Nimura Y, Nakagawara A, Obinata M, Ikawa S: Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med 1998;4:839-843.
6. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, Andrews NC, Caput C, McKeon F: p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998;2:305-316.
7. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, Caput D: Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other cancers. Cell 1997;90:809-819.
8. Jost CA, Marin MC, Kaelin WG: p73 is a simian p53-related protein that can induce apoptosis. Nature 1997;389:191-194.
9. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, Tabin C, Sharpe A, Caput S, Crum C, McKeon F: p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999;398:714-718.
10. Grob TJ, Fey MF, Tobler A: The two faces of p73. Cell Death Diff 2002;9:237-245.
11. Pozniak CD, Radinovic S, Yang A, McKeon F, Kaplan DR, Miller FD: An anti-apoptotic role for the p53 family member p73 during developmental neuron death. Science 2000;289:304-306.
12. Kartasheva NN, Contente A, Lenz-Stoppler C, Roth J, Dobbelstein M: Δp73 can modulate the expression of various genes in a p53-independent fashion. Oncogene 2002;21:4715-4727.
13. Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M, Chals E, Moll UM: ΔNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is upregulated in human tumors. J Exp Med 2002;196:765-780.
14. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, Jacks T: p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002;416:560-564.
15. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A: p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999;398:708-713.
16. Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, Vagner C, Bonnet H, Dikkes P, Sharpe A, McKeon F, Caput D: p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000;404:99-103.
17. Pellegrini G, Dellambra E, Golisano O, Martinelli E, Fantozzi I, Bondanza S, Ponzin D, McKeon F, De Luca M: p63 identifies keratinocyte stem cells. Proc Natl Acad Sci USA 2001;98:3156-3161.
18. Crook T, Nicholls JM, Brooks L, O'Nions J, Allday MJ: High level of expression of ΔNp63: A mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC). Oncogene 2000;19:3439-3444.
19. Hibi K, Trink BMP, Westra WH, Caballero OL, Hill DE, Ratoviski EA, Jen J, Sidransky D: AIS is an oncogene amplified in squamous cell carcinomas. Proc Natl Acad Sci USA 2000;97:5462-5467.
20. Park JJ, Sun D, Quade BJ, Flynn C, Sheets EE, Tang A, McKeon F, Crum CP: Stratified mucin-producing intraepithelial lesions of the cervix: Adenosquamous or columnar cell neoplasia? Am J Surg Pathol 2000;24:1414-1419.
21. Pruneri G, Pignataro L, Manzotti M, Carboni N, Ronchetti D, Neri A, Cesana BM, Viale G: p63 in laryngeal squamous cell carcinomas: Evidence for a role of TA-p63 down-regulation in tumorigenesis and lack of prognostic implications of p63 immunoreactivity. Lab Invest 2002;82:1327-1334.
22. Nylander K, Coates PJ, Hall PA: Characterization of the expression pattern of p63α and ΔNp63α in benign and malignant oral epithelial lesions. Int J Cancer 2000;87:368-372.
23. Puig P, Capodieci P, Drobnjak M, Verbel D, Prives C, Cordon-Cardo C, Di Como C: p73 expression in human normal and tumor tissues: Loss of p73α expression is associated with tumor progression in bladder cancer. Clin Cancer Res 2003;9:5642-5651.
24. Stiewe T, Pützer BM: Role of p73 in malignancy: Tumor suppressor or oncogene? Cell Death Diff 2002;9:2226-2230.
25. Tannapfel A, Wasner M, Krause K, Geissler F, Katalinic A, Hauss J, Mossner J, Engeland K, Witteking C: Expression of p73 and its relation of histopathology and prognosis in hepatocellular carcinoma. J Natl Cancer Inst 1999;91:1154-1158.
26. Sun XF: p73 overexpression is a prognostic factor in patients with colorectal adenocarcinoma. Clin Cancer Res 2002;8:165-170.
27. Dominguez G, Silva JM, Silva J, Garcia JM, Sanchez A, Navarro A, Gallego I, Provencio M, Espana P, Bonilla F: Wild type p73 overexpression and high-grade malignancy in breast cancer. Breast Cancer Res 2001;66:183-190.
28. Faridoni-Laurens L, Bosq J, Janot F, Vayssade M, Le Bihan ML, Kaghad M, Caput D, Bénard J, Ahomadegbe JC: p73 expression in basal layers of head and neck squamous epithelium: A role in differentiation and carcinogenesis in concert with p53 and p63? Oncogene 2001;20:5302-5312.
29. Agami R, Blandino G, Oren M, Shaul Y: Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature 1999;399:809-813.
30. Gong JG, Constanzo A, Yang HQ, Melino G, Kaelin WG, Levrero M, Wang JY: The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999;399:806-809.
31. Yuan ZM, Shioya H, Ishiko T, Sun X, Gu J, Huang YY, Lu H, Kharbanda S, Weichselbaum R, Kufe D: p73 is regulated by tyrosine kinase c-abl in the apoptotic response to DNA damage. Nature 1999;399:814-817.
32. Gonzalez S, Prives C, Cordon-Cardo C: p73alpha regulation by chk1 in response to DNA-damage. Mol Cell Biol 2003;23:8161-8171.
33. Liefer KM, Koster MI, Wang XJ, Yang A, McKeon F, Roop DR: Down-regulation of p63 is required for epidermal UV-B-induced apoptosis. Cancer Res 2000;60:4016-4020.
34. Bier H, Hoffmann T, Eikelmann P, Hafner D: Chemosensitivity of head and neck squamous carcinoma cell lines is not primarily correlated with glutathione level but is modified by glutathione depletion. J Cancer Res Clin Oncol 1996;122:653-658.
35. Hoffmann T, Hafner D, Balló H, Haas I, Bier H: Antitumor activity of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma (HNSCC) lines. Anticancer Res 1997;17:4419-4426.
36. Fritsche M, Haessler C, Brandner G: Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993;8:307-318.
37. Choi H-G, Batsakis JG, Zhan F, Sturgis E, Luna MA, El-Naggar AK: Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis. Hum Pathol 2002;33:158-164.
38. Harmes DC, Bresnick E, Lubin EA, Watson JK, Heim KE, Curtin JC, Suskind AM, Lamb J, DiRenzo J: Positive and negative regulation of ΔN-p63 promoter activity by p53 and ΔN-p63α contributes to differential regulation of p53 target genes. Oncogene 2003;22:7607-7616.
39. Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T, Ikawa S: Possible oncogenic potential of ΔNp73: A newly identified isoform of human p73. Cancer Res 2002;62:636-641.
40. Tschan MP, Grob TJ, Peters UR, De Laurenzi V, Huegli B, Kreuzer K-A, Schmidt CA, Melino G, Fey MF, Tobler A, Cajot J-F: Enhanced p73 expression during differentiation and complex p73 isoforms in myeloid leukemia. Biochem Biophys Res Commun 2000;277:62-65.
41. Zwahlen D, Tschan MP, Grob TJ, Peters UR, Fink D, Haenggi W, Altermatt HJ, Cajot J-F, Tobler A, Fey MF, Aebi S: Differential expression of p73 splice variants and protein in benign and malignant ovarian tumors. Int J Cancer 2000;88:66-70.
42. Waltermann A, Kartasheva NN, Dobbelstein M: Differential expression of p63 and p73 expression. Oncogene 2003;22:5686-5693.
43. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG: Chemosensitivity linked to p73 function. Cancer Cell 2003;3:403-410.
44. Hauser U, Balz V, Carey T, Grénman R, Scheckenbach K, Bier H: Reliable detection of p53 mutations in squamous cell carcinomas of the head and neck requires full length sequencing analysis. Head Neck 2002;24:868-873.